Evidence map›Paper›PMID 40936517›Full record

ReviewInternational journal of nanomedicine2025

Application of Pharmaceutical Nanotechnologies for Chinese Herbal Medicines in the Treatment of Pulmonary Diseases and Lung Cancer.

Xiaoping Yang, Hongxin Niu, Wen Jiang, Wanpeng Yu, Wenqing Jiang

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaoping YangQingdao Traditional Chinese Medicine Hospital, Qingdao Hiser Hospital Affiliated of Qingdao University, Qingdao, Shandong, People's Republic of China.
Hongxin NiuDepartment of Intervention, Qilu Hospital (Qingdao), Qingdao, Shandong, People's Republic of China.
Wen JiangQingdao Traditional Chinese Medicine Hospital, Qingdao Hiser Hospital Affiliated of Qingdao University, Qingdao, Shandong, People's Republic of China.
Wanpeng YuQingdao Medical College, Qingdao University, Qingdao, Shandong, People's Republic of China.
Wenqing JiangQingdao Traditional Chinese Medicine Hospital, Qingdao Hiser Hospital Affiliated of Qingdao University, Qingdao, Shandong, People's Republic of China.ORCID 0000-0003-4955-2503

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chinese herbal medicines (CHMs) is the crystallization of wisdom accumulated by the Chinese nation over thousands of years. With the development and advancement of technology, extensive research has been conducted on the pharmacological activities of active components in CHMs. Natural constituents from medicinal plants exhibit rich scaffold diversity and structural complexity, playing crucial roles in the pharmacological effects of CHMs. However, many CHMs components have been found to suffer from poor water solubility, low stability, and limited bioavailability, which significantly restrict their clinical applications. In recent years, nanomedicine has been leveraging the power of nanotechnology to fully exploit its distinctive advantages. In the field of CHMs, the introduction of nanonization technology has enhanced the therapeutic efficacy of CHMs formulations. Especially the use of nano-modified CHMs solely derived from natural products has overcome several "bottlenecks" associated with chemical nanodelivery systems-such as insufficient drug loading, high production costs, potential systemic toxicity, and immunogenicity-emerging as an innovative and promising platform for disease treatment. Here, we review recent advancements in pharmaceutical nanotechnologies for CHMs in the treatment of pulmonary diseases and lung cancer. These nano-modified CHMs include nanoemulsions, self-assembled nanoparticles, nanocrystals, herbal-derived exosomes, and carbon dot-based nanozymes formulated from natural medicinal plants. They demonstrate unique advantages in enhancing the pharmacological effects of natural bioactive compounds and treating pulmonary disorders and lung cancer. This provides novel insights into the development of nano-modified CHMs in the treatment of pulmonary disease and lung cancer.

Indexed as

Drugs, Chinese HerbalLung DiseasesLung NeoplasmsNanomedicineAnimalsDrug Delivery SystemsHumansNanoparticlesNanotechnologyDrugs, Chinese HerbalChinese herbal medicineslung cancernanotechnologiespulmonary disease

Identifiers

PMID40936517
PMCPMC12420921

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.